Research programme: RNA-based therapeutics - Roche/Shire

Drug Profile

Research programme: RNA-based therapeutics - Roche/Shire

Latest Information Update: 04 Dec 2014

Price : $50

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 26 Aug 2013 Research is ongoing in Denmark
  • 08 Mar 2011 Research is ongoing in Denmark
  • 24 Aug 2009 Early research in Undefined indication in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top